Pfizer launches Web site for tracking pipeline compounds

Share this article:
Pfizer today launched a new Web site that allows investors and members of the scientific and medical communities to track the progress of compounds in the firm’s research and development pipeline. The new Web site, at www.pfizer.com/pipeline, features descriptions of the eleven major therapeutic areas and 63 diseases at the center of Pfizer’s R&D efforts. The Web site will be updated twice-a-year, Pfizer said. “We have the largest and most diverse pipeline in our history. One of our most important business priorities is bringing these compounds forward so that they reach the patients who need them and drive our long-term growth,” said John LaMattina, Pfizer’s president of global research and development. “We have set specific and realistic goals for introducing a steady stream of new products in the years ahead -- four internally developed products by 2011 plus two externally acquired products by 2010 -- and we look forward to reporting on our progress.” Today’s launch of the Web site follows Pfizer’s commitment made at its Nov. 30 R&D day, to make pipeline details available before the end of 2006. The Web site launch also comes in the wake of Pfizer’s announcement earlier this month to halt all clinical trials for torcetrapib, once the most highly touted drug in its pipeline, due to safety concerns. The decision has forced the firm to accelerate its cost-cutting measures and acquisition activity and raised questions about the future of the company, analysts said.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.